Covid-19: Zydus Cadila seeks DCGI nod for treating mild symptoms
New Delhi: Cadila Healthcare Ltd (Zydus Cadila) has sought permission from India’s drugs regulator for starting the next phase of human clinical trials for its biological therapy to treat mild Covid-19 cases. On Thursday, the Ahmedabad-based company said the therapy named ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs), targets the SARS-CoV-2 spike protein. […]
